-
Beta-Blockers Therapy for the Treatment of Hypertension; Treatments for Acute Migraine; Statin Therapy for ACS Patients; The Correct Dosing for Onychomycosis; FDA Actions
-
Souka and colleagues have recently published a review that should be very helpful to the clinician confronted with the dilemma of counseling patients whose fetuses have increased nuchal translucencies (NTs) in the first trimester.
-
Endometrial cancer is the most common gynecologic malignancy and is usually characterized by limited disease at presentation. Among the number of known prognostic factors, grade of disease is one frequently used to triage patients for formal surgical staging.
-
-
Epidemiologists at the National Cancer Institute organized and conducted a retrospective cohort study, recruiting patients treated between 1965 and 1988 from endocrine and infertility practices in 5 academic centers.
-
A study that attracted some attention at the Society for Maternal-Fetal Medicine meeting last year was recently published in the American Journal of Obstetrics and Gynecology. It dealt with the usefulness of fetal fibronectin (fFN) and cervical length (CL) in predicting which patients with preterm contractions (PTC) were truly in preterm labor (PTL).
-
Erectile Dysfunction and Visual Disturbance; Mixed News on Statins; FDA Actions
-
Delays in starting radiation therapy for high-risk localized prostate cancer were shown in this retrospective review to be associated with a greater risk for disease relapse, as witnessed by PSA recurrence. For patients with low-risk disease, however, comparable delays were not associated with greater risk for relapse.
-
Survivors 2 years or more after autologous stem cell transplant for AML, ALL, NHL, and HD remain at significant risk of death, with 29% mortality, almost entirely between 2 and 10 years after transplant. While 56% died of relapse of the primary disease, 43% died from treatment related complications, many of whom suffered from therapy related MDS or AML.
-
The IRI/LV/5-FU and OXA/LV/5-FU regimens demonstrated equally substantial efficacies and manageable toxicity profiles in the first-line treatment of patients with advanced CRC. However, IRI/LV/5-FU may be the preferable regimen to avoid significant neurotoxicity associated with OXA/LV/5-FU.